Floatz logo

VINCRISTINE SULFATE

Refractory B Lymphoblastic Lymphoma

ECOG-ACRIN Cancer Research GroupSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Refractory B Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
University of Washington
Phase 2BB
PREDNISONE TABLETS
University of Washington
Phase 2B
Inotuzumab Ozogamicin
University of Washington
Phase 2B
Inno-206
University of Washington
Phase 2B
Cyclophosphamide
University of Washington
Phase 2B

View all 16 →

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →